Skip to Content
  • Title
    CEO
  • Company
    Novo Nordisk

The world’s largest insulin maker has stuck with a big bet on diabetes, which has meant huge margins as the disease exacts an ever-widening toll. During Sorensen’s 16 years as CEO, he consistently delivered healthy growth, with revenues five times as big as when he took the helm and profits reaching a record $5.6 billion (on $16.7 billion in sales) in the past 12 months. Now, though, Novo Nordisk faces pricing pressures and Sorenson will retire at year’s end.